Aytu BioScience Inc. (AYTU)

[fatcat2]

In a statement, Josh Disbrow, CEO at Aytu Bioscience, had the following to offer:

“We continue to track in line with our internal projections and expectations, and remain very enthusiastic about the ongoing growth and uptake of Natesto. The growing Natesto prescription and prescriber numbers continue to demonstrate the very real need for a truly improved option for the millions of men in the U.S. with hypogonadism. Despite this significant early growth, we believe that this is still just the start of establishing Natesto as the preferred TRT product in the U.S. market.”